Myelofibrosis, a clonal stem-cell disorder which is difficult to cure, The treatment for most of patients is
conservative treatment, but the treatment effect is not ideal.
Lenalidomide as a novel
immunomodulator in the treatment of
blood diseases showed good results in recent years, Its studies have shown that
lenalidomide in
myelofibrosis also showed a certain effect. As companed with single
drug lenalidomide, the
thalidomide has a higher response rate, clinical symptoms improved significantly.
Ruxolitinib, JAK2 inhibitor, combined with
lenalidomide not only can improve the quality of life of patients, but also extend the survival of patients. In addition,
lenalidomide combined with
prednisone for the treatment of
bone marrow fibrosis is more effective and more safe,
lenalidomide can significantly improve the clinical symptoms of patients, especially
anemia, and
prednisone can reduce the hematologic toxicity of lenalidomids. The purpose of this review is to evaluate the efficacy and safety of
lenalidomide in the treatment of
myelofibrosis, and focuses on the newest clinical research and application progress of
lenalidomide for
myelofibrosis.